|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | |||||
| Stock-based compensation expense | |||||
| Depreciation and amortization expense | |||||
| Intangible asset impairment charges | |||||
| Deferred income taxes | |||||
| Losses on equity securities | |||||
| Decrease in fair value of contingent consideration | |||||
| Other non-cash items, net | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, net | |||||
| Inventories | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Other liabilities | |||||
| Net cash provided by (used in) operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchases of available-for-sale debt securities | |||||
| Sales and maturities of available-for-sale debt securities | |||||
| Purchases of property and equipment | |||||
| Proceeds related to equity securities | |||||
| Net payments related to finite-lived intangible assets | |||||
| Acquisition of available-for-sale debt securities from Alpine Immune Sciences, Inc. | |||||
| Payment to acquire ViaCyte, Inc., net of cash acquired | |||||
| Other investing activities | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Issuances of common stock under benefit plans | |||||
| Repurchases of common stock | |||||
| Payments in connection with common stock withheld for employee tax obligations | |||||
| Payments on finance leases | |||||
| Proceeds from finance leases and other financing activities | |||||
| Other financing activities | |||||
| Net cash used in financing activities | |||||
| Effect of changes in exchange rates on cash | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash—beginning of period | |||||
| Cash, cash equivalents and restricted cash—end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for income taxes | |||||
| Cash paid for interest | |||||
| Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets | |||||
Loading...
